Navigation Links
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date:6/1/2011

works as designed to address the underlying immune suppression observed in metastatic RCC patients, while also generating a highly specific and durable T-cell response that appears to improve clinical outcomes in terms of PFS, when combined with sunitinib," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "This is the first prospective analysis of immunodynamics in RCC patients receiving sunitinib in combination with an immunotherapy, and we plan to confirm these positive results in a randomized setting in a Phase 3 clinical trial."

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com

Contacts:

David Schull or Andreas
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
2. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
7. Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)( ... the development of oral drug delivery systems, announces ... to discuss the clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes ... Eastern time. Shareholders and other interested ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3
... 6 month results from long term durability study presented ... Section meeting of the American Urological Association, ... of innovative therapies in women,s health, announced today that,six ... to,evaluate the long term durability of the Renessa(R) treatment ...
... Community Oncology,Alliance (COA), representing community cancer centers ... & Medicaid Services (CMS),reconsider its decision to ... to,vital anemia-fighting drugs. Effective July 30, 2007, ... oncologists, use of,anemia-fighting drugs, referred to as ...
Cached Medicine Technology:New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence 2New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence 3Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions 2
(Date:10/31/2014)... 2014 (HealthDay News) -- Carving pumpkins and trick-or-treating may ... children to emergency rooms in the United States every ... had the fifth highest number of ER visits involving ... data from the National Electronic Injury Surveillance System. ... head, noted the American Academy of Orthopaedic Surgeons and ...
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. ... all public health tactics known to prevent Ebola transmission ... epidemic, a new study reports. Four practices in ... way, immediately isolating new patients, tracing people potentially exposed ... care workers -- can stop the epidemic within six ...
(Date:10/31/2014)... National Institutes of Health will facilitate communication among ... health research, from diagnosis to treatment. The Research ... the National Institute of Mental Health (NIMH), part ... institute,s RDoC initiative. , The aim of ... of research that translates basic science into clinical ...
(Date:10/31/2014)... are clear differences in the brains of people with ... new research indicates. Scientists at Stanford University ... diagnose this baffling condition and shed light on how ... misdiagnosed or labeled as hypochondriacs. Using three ... [chronic fatigue syndrome] patients, brains diverge from those of ...
(Date:10/31/2014)... (HealthDay News) -- A comparison of two of the ... laparoscopic gastric bypass helped patients shed more excess pounds ... of short-term complications and long-term hospitalizations. Gastric-bypass surgery ... so your body does not absorb all the calories ... of Health. Gastric banding is a type of weight-loss ...
Breaking Medicine News(10 mins):Health News:Halloween at the ER Is No Treat 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 3Health News:NIMH creates new unit to support its research domain criteria initiative 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 3Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3
... Mass. -- A subtle mutation affecting the epigenome - a ... lead to an inherited form of mental retardation that affects ... also involves cleft lip or cleft palate, appears to hinge ... offer several potential drug targets. The study, published online ...
... Professor of Public Health and Director of Health Promotion ... evidence that supports relationships seen in adolescents between insulin ... fat and identifies additional potential early markers of insulin ... including fat in muscle cells, blood pressure, physical activity, ...
... HealthDay Reporter , FRIDAY, July 9 (HealthDay News) -- One ... of Avandia, new doubts surfaced Friday on a key trial ... A medical reviewer for the U.S. Food and Drug ... that drugmaker GlaxoSmithKline,s "mishandling" of trial results may have ...
... the 52nd meeting of the American Association of Physicists ... 22, 2010 in Philadelphia, PA, thousands of scientists and ... developments in medical imaging and radiation therapy, examine new ... ethical and regulatory issues that face the field today. ...
... Researchers at Brown University have found that the length of ... doubled during the last 10 years. The study, which will ... the American Geriatrics Society , evaluated hospice use in U.S. ... treatment time has increased from 46 to 93 days. The ...
... HCG True Diet offers ... ... photos and revamped the before and after section of the website. The pictures can be ... taken of a patient before they start the HCG True Diet and after they finish the ...
Cached Medicine News:Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 3Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 2Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 3Health News:FDA Reviewer Questions Results of Key Avandia Trial 2Health News:FDA Reviewer Questions Results of Key Avandia Trial 3Health News:FDA Reviewer Questions Results of Key Avandia Trial 4Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 2Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 3Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 4Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 5Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 6Health News:Study: Medicare policy may account for growing length of hospice stays in nursing homes 2Health News:See New HCG Diet Before and After Photos 2
MONOJECT SUPRA/HONE Blood Collection Needles - Thin Wall...
VACUETTE PaediatricMulti-Sample Needle...
... Blood Collection Needles are preominantly used for ... single-use. The colour of the needle protective ... needle gauges. For example, yellow symbolises the ... 21 G (0.80 mm) and black 22 ...
This is adapted to microplate or card....
Medicine Products: